Home HealthMedical DevicesWellness

Glucose Monitoring Research Drives More Promises Than Answers

PatrickDriscoll
2 Min Read

Glucose monitoringIf I had a nickel for every headline like this that ultimately failed, like the technology, to actually achieve the promise, I would be on a tropical beach sipping pina coladas:

“Glucose monitoring for diabetes made easy with a blood-less method.” (link)

Glucose monitoringIf I had a nickel for every headline like this that ultimately failed, like the technology, to actually achieve the promise, I would be on a tropical beach sipping pina coladas:

“Glucose monitoring for diabetes made easy with a blood-less method.” (link)

More Read

Improve Autistic Children’s Mental Health by Teaching Social Skills

5 Key Considerations in Packaging and Shipping Medical Devices
The Power of Movement: Overcoming Injuries with Proven PT Techniques
3 Healthy Habits You Should Start to Prevent Future Injuries
Strategies for Managing Grief and Promoting Emotional Wellness After Losing a Loved One

Technologies in development for less-invasive or non-invasive glucose monitoring are legion, and many are very promising, but you can’t fill out a deposit slip with these promises. Frequently, such alternatives are based on the premise of quantifying blood glucose by sensitively detecting glucose in other fluids (interstitial fluid, tears, saliva, urine, etc.) that do not require the use of lancets to draw blood. However, despite their sensitivity and other sophistication in detecting minute quantities of glucose, their “arm’s length” to actual blood glucose compounds the challenge by requiring that the test reproducibly correlate the sample values with actual, current blood glucose levels.

The challenge stands unanswered, while the burgeoning population of endlessly finger-pricked diabetics remains painfully unsatisfied.

As a practical reality, continuous blood glucose monitors like those from Dexcom and Medtronic offer far more to the diabetic population, not only by avoiding finger pricks but also by revealing the patterns in blood glucose levels over time as a result of activity, carbohydrate intake, insulin bolus, insulin basal rate, stress and countless other patient-specific determinants.

Share This Article
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Previous Article The Geographic Divide: How Federalism Has Formalized Health Disparities
Next Article Coordinated Care Begins With The Patient
Exit mobile version